Skip to main content
logo
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
30.77
+1.52 (5.20%)
At close: Jun 26, 2026, 4:00 PM EDT
30.00
-0.77 (-2.50%)
After-hours: Jun 26, 2026, 6:54 PM EDT

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
North America Revenue
378.46M377.00M340.46M
North America Revenue Growth
0.39%10.73%10.85%
Latin America Revenue
157.33M170.00M130.71M
Latin America Revenue Growth
-7.45%30.06%69.01%
Europe Revenue
115.28M108.00M80.12M
Europe Revenue Growth
6.74%34.79%68.56%
Asia-Pacific Revenue
18.35M18.00M8.93M
Asia-Pacific Revenue Growth
1.97%101.57%301.53%
Revenue (Other)
279.00K--230.00K
Revenue (Total)
669.71M673.00M560.00M
Revenue (Total) Growth
-0.49%20.18%29.03%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Crysvita Revenue
167.73M177.00M134.71M
Crysvita Revenue Growth
-5.24%31.39%77.96%
Dojolvi Revenue
97.48M96.00M88.19M
Dojolvi Revenue Growth
1.54%8.85%24.86%
Evkeeza Revenue
66.29M59.00M32.16M
Evkeeza Revenue Growth
12.36%83.45%783.09%
Mepsevii Revenue
35.31M37.00M30.35M
Mepsevii Revenue Growth
-4.57%21.91%-0.30%
Total Product Revenue
366.81M369.00M285.42M
Total Product Revenue Growth
-0.59%29.29%58.20%
Crysvita Royalty Revenue
302.62M304.00M274.82M
Crysvita Royalty Revenue Growth
-0.45%10.62%50.46%
Revenue (Other)
279.00K--230.00K
Revenue (Total)
669.71M673.00M560.00M
Revenue (Total) Growth
-0.49%20.18%29.03%